ASCO’s Activist Side: Abstract Preview Highlights Personalized Medicine, Cost Of Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Selection of key research notably includes no real advances in commercial drug development.
You may also be interested in...
Economic Pressures Increasingly Concern Private-Pay Oncology
Once shy about discussing expenses with patients, oncologists increasingly are opening up about the nitty gritty of drug costs during office visits
Economic Pressures Increasingly Concern Private-Pay Oncology
Once shy about discussing expenses with patients, oncologists increasingly are opening up about the nitty gritty of drug costs during office visits
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises